Results 11 to 20 of about 15,060 (265)

Palmoplantar Pustulosis: A Systematic Review of Risk Factors and Therapies

Psoriasis: Targets and Therapy, 2023
Kristine Heidemeyer,1,2 Marco May Lee,3 Simone Cazzaniga,1,2 Nikhil Yawalkar,1 Luigi Naldi2,4 1Department of Dermatology, Inselspital University Hospital of Bern, Bern, Switzerland; 2Centro Studi GISED, Bergamo, Italy; 3Section of Dermatology, Department
Heidemeyer K, May Lee M, Cazzaniga S, Yawalkar N, Naldi L   +4 more
doaj   +2 more sources

Acute generalized exanthematous pustulosis during apalutamide treatment in a patient with prostate cancer

IJU Case Reports, 2022
Introduction Acute generalized exanthematous pustulosis is a type of severe cutaneous drug adverse reaction. While apalutamide is known for its high incidence of cutaneous adverse events, it remains unknown whether acute generalized exanthematous ...
Tomoko Honda, Yoichiro Tohi, Yo Kaku, Nachino Kimura, Takuma Kato, Reiji Haba, Teruki Dainichi, Mikio Sugimoto   +7 more
doaj   +2 more sources

Acute Generalized Exanthematous Pustulosis: Clinical Characteristics, Pathogenesis, and Management

Dermatology, 2023
Background: Acute generalized exanthematous pustulosis (AGEP) is a potentially severe adverse cutaneous drug reaction, which typically occurs within 24–48 h after the intake of the culprit drug.
P. Stadler, Anna Oschmann, Katrin Kerl-French, J. Maul, E. Oppel, Barbara Meier‐Schiesser, L. French   +6 more
semanticscholar   +1 more source

Spesolimab Efficacy and Safety in Patients with Moderate-to-Severe Palmoplantar Pustulosis: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase IIb, Dose-Finding Study

Dermatologic Therapy, 2023
We evaluated the anti-interleukin-36 receptor antibody spesolimab in patients with moderate-to-severe palmoplantar pustulosis (PPP). This phase IIb trial comprised a loading dose period to week (W) 4, then maintenance dosing to W52.
A. D. Burden, R. Bissonnette, A. Navarini, Masamoto Murakami, A. Morita, T. Haeufel, Binqi Ye, Frank Baehner, Tadashi Terui   +8 more
semanticscholar   +1 more source

Efficacy and Safety of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: Results from a Phase 2, Randomized, Placebo-Controlled Study

American Journal of Clinical Dermatology, 2023
Background Palmoplantar pustulosis (PPP) is a pruritic, painful, recurrent, and chronic dermatitis with limited therapeutic options. Objective To evaluate the efficacy and safety of apremilast for the treatment of Japanese patients with PPP and ...
T. Terui, Y. Okubo, Satomi Kobayashi, S. Sano, A. Morita, S. Imafuku, Y. Tada, Masatoshi Abe, M. Yaguchi, Natsuka Uehara, Takahiro Handa, Masayuki Tanaka, Wendy Zhang, M. Paris, M. Murakami   +14 more
semanticscholar   +1 more source

Clinical Characteristics, Disease Course, and Outcomes of Patients With Acute Generalized Exanthematous Pustulosis in the US.

JAMA dermatology, 2022
Importance Acute generalized exanthematous pustulosis (AGEP) is a rare, severe cutaneous adverse reaction associated with systemic complications. Currently available data are largely limited to small retrospective case series. Objective To describe the
A. Creadore, S. Desai, A. Alloo, A. Dewan, M. Bakhtiar, Carla N. Cruz-Diaz, A. Femia, L. Fox, Kimberly L. Katz, R. Micheletti, C. Nelson, A. Ortega‐Loayza, J. Patrinely, Molly E Plovanich, M. Rosenbach, Sheila Shaigany, B. Shields, Jamal Z Saleh, Zakariyah Sharif-Sidi, K. Shinkai, Jacob Smith, Chang Su, K. Wanat, Jill K Wieser, S. Wright, M. Noe, A. Mostaghimi   +26 more
semanticscholar   +1 more source

Response of palmoplantar pustulosis to upadacitinib

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2023
Dear Editors, Palmoplantar pustulosis (PPP) is a rare disease affecting the palms and soles. It is characterized by sterile pustules on erythematous skin.1 The four isoforms of Janus kinases (JAK) are crucial intracellular mediators of type I and II ...
J. Mohr, Neda Rahbar Kooybaran, M. P. Schön, R. Mössner   +3 more
semanticscholar   +1 more source

Refractory Palmoplantar Pustulosis Successfully Treated with JAK Inhibitor Tofacitinib: A Case Series

Infection and Drug Resistance, 2023
Background Palmoplantar pustulosis (PPP) is a common chronic and recurrent skin disease of the palms and soles with significant pain, mental distress, and functional disability.
Qingqing Xu, Xiaochen Wang, Anbo Yang, Guo Wei   +3 more
semanticscholar   +1 more source

Apremilast monotherapy for palmoplantar pustulosis: Report of three cases

SAGE Open Medical Case Reports, 2021
Palmoplantar pustulosis or palmoplantar pustular psoriasis is chronic skin conditions, characterised by eruptions of sterile pustules on an erythematosquamous background. High-quality data on the treatment of palmoplantar pustulosis are limited, and none
Maruška Marovt, Pij B Marko
doaj   +1 more source

Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study

Dermatologic Therapy, 2021
Palmoplantar pustulosis (PPP) is a chronic, inflammatory skin disease, with high disease burden, that is often refractory to treatment. There is a high unmet clinical need for the treatment of patients with PPP.
U. Mrowietz, A. Burden, A. Pinter, K. Reich, K. Schäkel, P. Baum, Y. Datsenko, Hongjie Deng, S. Padula, C. Thoma, R. Bissonnette   +10 more
semanticscholar   +1 more source